Skip to main content

Table 2 Related adverse reactions of ADT combined with DTX chemotherapy

From: Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis

Adverse events

number(%)

Hematologic toxicity

 Grade I–II neutropenia

27 (42.8)

 Grade III–IV neutropenia

6 (9.5)

 Febrile neutropenia, FN

6 (9.5)

Digestive system toxicity

 Nausea or vomiting

18 (28.6)

 Defecation action changes

9 (14.3)

 Grade III hypohepatia

3 (4.8)

Skin mucosal toxicity

 Hair loss

21 (33.3)

 Skin rash or itching

6 (9.5)

Fluid retention

 Mild edema of limbs

9 (14.3)